JPWO2023004304A5 - - Google Patents
Info
- Publication number
- JPWO2023004304A5 JPWO2023004304A5 JP2024503351A JP2024503351A JPWO2023004304A5 JP WO2023004304 A5 JPWO2023004304 A5 JP WO2023004304A5 JP 2024503351 A JP2024503351 A JP 2024503351A JP 2024503351 A JP2024503351 A JP 2024503351A JP WO2023004304 A5 JPWO2023004304 A5 JP WO2023004304A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- region
- immunoconjugate
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163223786P | 2021-07-20 | 2021-07-20 | |
| US63/223,786 | 2021-07-20 | ||
| US202163288111P | 2021-12-10 | 2021-12-10 | |
| US63/288,111 | 2021-12-10 | ||
| PCT/US2022/073877 WO2023004304A1 (en) | 2021-07-20 | 2022-07-19 | Cd8-binding polypeptides and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024526835A JP2024526835A (ja) | 2024-07-19 |
| JP2024526835A5 JP2024526835A5 (https=) | 2025-07-18 |
| JPWO2023004304A5 true JPWO2023004304A5 (https=) | 2025-07-18 |
Family
ID=82898944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024503351A Pending JP2024526835A (ja) | 2021-07-20 | 2022-07-19 | Ｃｄ８結合ポリペプチド及びその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250320295A1 (https=) |
| EP (1) | EP4373854A1 (https=) |
| JP (1) | JP2024526835A (https=) |
| CA (1) | CA3225092A1 (https=) |
| TW (1) | TW202321283A (https=) |
| WO (1) | WO2023004304A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025179294A2 (en) | 2024-02-22 | 2025-08-28 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| ES2375931T3 (es) | 1997-12-05 | 2012-03-07 | The Scripps Research Institute | Humanización de anticuerpo murino. |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| PT1678314E (pt) | 2003-10-22 | 2012-11-27 | Keck Graduate Inst | Métodos de síntese de polipéptidos heteromultiméricos em levedura utilizando uma estratégia de conjugação haplóide |
| CN1961003B (zh) | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | 人源化抗TGF-β抗体 |
| KR20210113265A (ko) * | 2019-01-07 | 2021-09-15 | 인히브릭스, 인크. | 변형된 il-2 폴리펩타이드를 포함하는 폴리펩타이드 및 이의 용도 |
| AU2020287373B2 (en) * | 2019-06-05 | 2026-01-29 | Asher Biotherapeutics, Inc. | Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function |
| WO2021001289A1 (en) * | 2019-07-02 | 2021-01-07 | F. Hoffmann-La Roche Ag | Immunoconjugates comprising a mutant interleukin-2 and an anti-cd8 antibody |
| WO2021046159A1 (en) * | 2019-09-04 | 2021-03-11 | Genentech, Inc. | Cd8 binding agents and uses thereof |
-
2022
- 2022-07-19 WO PCT/US2022/073877 patent/WO2023004304A1/en not_active Ceased
- 2022-07-19 EP EP22754735.3A patent/EP4373854A1/en active Pending
- 2022-07-19 JP JP2024503351A patent/JP2024526835A/ja active Pending
- 2022-07-19 US US18/578,133 patent/US20250320295A1/en active Pending
- 2022-07-19 TW TW111127060A patent/TW202321283A/zh unknown
- 2022-07-19 CA CA3225092A patent/CA3225092A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025102819A5 (https=) | ||
| JPWO2021155071A5 (https=) | ||
| JP2020536549A5 (https=) | ||
| JP2021520812A5 (https=) | ||
| JP2020516287A5 (https=) | ||
| Blanco et al. | Bispecific immunomodulatory antibodies for cancer immunotherapy | |
| JPWO2019200022A5 (https=) | ||
| US12029761B2 (en) | Guidance and Navigation Control proteins and method of making and using thereof | |
| JP2022116230A5 (https=) | ||
| US20220002425A1 (en) | Guidance and navigation control proteins and method of making and using thereof | |
| IL295878A (en) | Methods for producing cells expressing a chimeric antigen receptor | |
| JP2025078629A5 (https=) | ||
| JP2019513347A5 (https=) | ||
| JPWO2020135201A5 (https=) | ||
| JP2017513818A5 (https=) | ||
| JP2017507917A (ja) | 軟骨魚類由来の抗原認識ドメインを使用したキメラ抗原受容体 | |
| JPWO2020113164A5 (https=) | ||
| IL300062A (en) | Dual fused cytokine proteins containing IL-10 | |
| CN115698088A (zh) | 免疫细胞衔接器多特异性结合蛋白及其制备和应用 | |
| JPWO2023004304A5 (https=) | ||
| Li et al. | Nanobodies and their derivatives: pioneering the future of cancer immunotherapy | |
| CN119213028A (zh) | 结合γδ T细胞的多肽及其用途 | |
| JPWO2023034740A5 (https=) | ||
| JPWO2023133394A5 (https=) | ||
| Mortaheb et al. | Bispecific therapeutics: a state-of-the-art review on the combination of immune checkpoint inhibition with costimulatory and non-checkpoint targeted therapy |